SciBase Holding AB (SE:SCIB)
:SCIB
Top Page
SciBase Holding AB
(SCIB)
Select Model
Select Model
Rating:47Neutral
Price Target:
kr0.37
▲(12.73% Upside)
Action:ReiteratedDate:04/03/26
The score is held down primarily by weak financial performance—large, widening losses, worsening cash burn, and materially reduced equity—despite strong revenue growth. Technicals are supportive with an established uptrend, but overbought signals add risk. Valuation support is limited because the company is loss-making and no dividend yield is available.
Positive Factors
Sustained revenue growth
Multi-year revenue growth from 9.5M to 40.5M through 2025 signals durable commercial traction for the Nevisense platform and improving market adoption. Sustained top-line expansion supports scale economies, larger installed base and rising recurring procedure volumes that underpin longer-term revenue visibility.
Negative Factors
Widening operating losses
Operating losses expanded sharply in 2025 despite revenue gains, indicating persistent high operating costs or intensive commercial spend. Continued large EBIT deficits threaten the path to sustainable profitability and imply ongoing dependence on external funding unless costs are brought under control or revenue scale accelerates materially.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue growth
Multi-year revenue growth from 9.5M to 40.5M through 2025 signals durable commercial traction for the Nevisense platform and improving market adoption. Sustained top-line expansion supports scale economies, larger installed base and rising recurring procedure volumes that underpin longer-term revenue visibility.
Read all positive factors
SciBase Holding AB (SCIB) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr306.50M
Dividend YieldN/A
Average Volume (3M)318.73K
Price to Earnings (P/E)―
Beta (1Y)-0.13
Revenue Growth36.15%
EPS Growth26.67%
CountrySE
Employees32
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.05
Shares Outstanding828,365,200
10 Day Avg. Volume218,776
30 Day Avg. Volume318,725
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)kr66.85M
SciBase Holding AB Business Overview & Revenue Model
Company Description
SciBase Holding AB (SCIB) is a Swedish medical technology company that specializes in developing innovative diagnostic solutions for skin cancer detection and monitoring. The company operates primarily in the healthcare sector, focusing on non-inv...
How the Company Makes Money
SciBase generates revenue primarily from sales of its Nevisense system and recurring sales of related consumables and service items. Key revenue streams typically include: (1) system revenue from selling or placing Nevisense instruments with clini...
SciBase Holding AB Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
28
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 40.46M | 29.70M | 23.25M | 17.89M | 11.73M |
| Gross Profit | 27.10M | 21.08M | 16.04M | 11.23M | 6.58M |
| EBITDA | -81.49M | -57.59M | -51.83M | -39.33M | -38.58M |
| Net Income | -87.06M | -61.13M | -55.59M | -39.90M | -41.69M |
Balance Sheet | |||||
| Total Assets | 52.17M | 61.73M | 64.33M | 49.85M | 85.46M |
| Cash, Cash Equivalents and Short-Term Investments | 22.60M | 11.24M | 34.12M | 18.83M | 65.61M |
| Total Debt | 0.00 | 4.18M | 6.80M | 8.12M | 2.86M |
| Total Liabilities | 45.51M | 25.08M | 21.28M | 24.62M | 14.66M |
| Stockholders Equity | 6.66M | 36.65M | 43.06M | 25.24M | 70.80M |
Cash Flow | |||||
| Free Cash Flow | -84.81M | -57.81M | -52.37M | -44.85M | -40.12M |
| Operating Cash Flow | -84.58M | -57.38M | -51.98M | -44.47M | -39.50M |
| Investing Cash Flow | -228.00K | -428.00K | -383.00K | -381.00K | -526.00K |
| Financing Cash Flow | 96.29M | 34.91M | 67.68M | -2.48M | 64.22M |
SciBase Holding AB Technical Analysis
Positive
0.33
Price Trends
0.28
Positive
0.27
Positive
0.28
Positive
Market Momentum
0.03
Negative
71.78
Negative
88.98
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCIB, the sentiment is Positive. The current price of 0.33 is above the 20-day moving average (MA) of 0.33, above the 50-day MA of 0.28, and above the 200-day MA of 0.28, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 71.78 is Negative, neither overbought nor oversold. The STOCH value of 88.98 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SCIB.
SciBase Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | kr122.48M | 20.88 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr306.50M | -1.43 | -253.54% | ― | 36.15% | 26.67% | |
44 Neutral | kr156.46M | -4.28 | -61.62% | ― | 14.18% | 72.73% | |
42 Neutral | kr20.11M | -2.89 | -60.56% | ― | 163.12% | 30.50% | |
42 Neutral | kr89.01M | -1.00 | ― | ― | -45.59% | 37.79% | |
41 Neutral | kr55.73M | -7.37 | ― | ― | ― | ― |
* Healthcare Sector Average
SE:SCIB
SciBase Holding AB
0.37
0.06
18.21%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
5.02
2.47
96.86%
SE:LXB
Luxbright AB
0.15
-0.58
-78.90%
SE:ARCOMA
Arcoma AB
8.56
0.18
2.15%
SE:NEOLA
Neola Medical AB
0.72
-1.87
-72.29%
SE:ICO
Iconovo AB
1.19
-0.77
-39.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.